Esperion Therapeutics, INC 8-K filings

Esperion Therapeutics, Inc. announced the successful completion of its merger with Essence Parent Inc., transitioning from a publicly traded company to a wholly owned subsidiary.

Esperion Therapeutics, Inc. announced that its stockholders have approved the Agreement and Plan of Merger with Essence Parent Inc. and its subsidiary, Essence MergerCo Inc.

Esperion Therapeutics announces the expiration of the HSR Waiting Period for its merger with ArchiMed SAS affiliate, Essence Parent Inc., with stockholder approval pending.

Esperion Therapeutics announces German regulatory approval for its merger with ArchiMed affiliate Essence Parent Inc., with other conditions pending.

Esperion Therapeutics held its 2026 annual meeting, where stockholders approved an amendment to increase shares available under the 2022 Stock Option and Incentive Plan.

Esperion Therapeutics has completed the acquisition of Corstasis Therapeutics, adding the FDA-approved nasal spray Enbumyst to its cardiovascular portfolio.

Esperion Therapeutics has entered a definitive agreement to acquire Corstasis Therapeutics for $75 million upfront, gaining FDA-approved Enbumyst and expanding its cardiovascular franchise.

Esperion announced preliminary full-year 2025 financial results, including significant sales growth, and introduced its long-term Vision 2040 strategy for global expansion and pipeline diversification.

Esperion Therapeutics reported a 69% year-over-year increase in total revenue for Q3 2025, reaching $87.3 million, and secured patent protection for its key products until April 2040.

Esperion Therapeutics appoints industry veteran John B. Harlow, Jr. as its new Chief Commercial Officer, effective November 17, 2025, to lead commercial strategy and global expansion.

Esperion Therapeutics announced the pricing of an underwritten public offering of 30 million shares of common stock at $2.50 per share, aiming to raise approximately $70.2 million in net proceeds.

Esperion Therapeutics reported its first quarter of operating income from ongoing business in Q2 2025, driven by robust revenue growth and strategic global expansion of its bempedoic acid franchise.

Esperion Therapeutics reports preliminary Q2 2025 financial results with significant revenue growth, achieving its first quarter of operating income from ongoing business, and securing key patent settlements.

Esperion Therapeutics reported robust second-quarter 2025 financial results, driven by significant U.S. net product revenue growth and achieving its first quarter of operating income from ongoing business.

Esperion Therapeutics, Inc. announced the appointment of Craig Thompson, a seasoned biopharmaceutical executive with over two decades of industry leadership, to its Board of Directors, effective July 1, 2025.

Esperion Therapeutics, Inc. announced that its stockholders approved the election of two Class III directors, executive compensation, the appointment of Ernst & Young LLP, and a significant increase in shares authorized for its 2022 Stock Option and Incentive Plan at its 2025 Annual Meeting.

Esperion Therapeutics reports a 53% decrease in total revenue for Q1 2025, primarily due to the absence of a milestone payment received in Q1 2024, though U.S. product revenue increased by 41%.

Esperion Therapeutics, Inc. reports that Eric Warren is stepping down as Chief Commercial Officer, effective April 18, 2025.

Esperion Therapeutics announces the appointment of Robert E. Hoffman as an independent director and Audit Committee Chairperson, while Nicole Vitullo and Antonio M. Gotto, Jr. resign from the board, effective June 1, 2025.

Esperion Therapeutics announces significant revenue growth for Q4 and full year 2024, driven by increased product sales and strategic collaborations, setting the stage for future profitability and portfolio expansion.

Esperion Therapeutics announced its 2025 financial guidance, projecting operating expenses between $215 million and $235 million.

Esperion Therapeutics has completed a private exchange and subscription transaction, issuing $100 million in convertible notes to refinance existing debt and for general corporate purposes.

Esperion Therapeutics has entered into agreements for a $210 million convertible debt financing, including a $150 million term loan, to refinance existing debt and for general corporate purposes.

Esperion Therapeutics announced a 52% year-over-year increase in total revenue to $51.6 million for the third quarter of 2024, fueled by growth in U.S. product sales and international partnerships.

Esperion Therapeutics announced a 186% year-over-year increase in total revenue for the second quarter of 2024, driven by U.S. product sales and a significant European royalty monetization.

Esperion Therapeutics' Chief Medical Officer, JoAnne Foody, will transition out of her role, with her employment ending on or before September 16, 2024.

Esperion Therapeutics has monetized its European royalties for $304.7 million and used the funds to eliminate its existing revenue interest debt.

Esperion Therapeutics' stockholders approved amendments to the company's stock option and employee stock purchase plans, increasing the number of shares available for issuance.

Esperion Therapeutics has initiated a patent infringement lawsuit against Micro Labs USA Inc. to protect its cholesterol-lowering drug, NEXLETOL, from generic competition.

Esperion Therapeutics announced a significant increase in revenue and a return to profitability in Q1 2024, driven by expanded labels for its cholesterol-lowering drugs and strong global sales.